Show simple item record

dc.contributor.authorTshweu, Lesego
dc.contributor.authorKatata, Lebogang
dc.contributor.authorKalombo, Lonji
dc.contributor.authorChiappetta, Diego
dc.contributor.authorHocht, Christian
dc.contributor.authorSosnik, Alejandro
dc.contributor.authorSwai, Hulda
dc.date.accessioned2019-10-16T08:24:47Z
dc.date.available2019-10-16T08:24:47Z
dc.date.issued2014-10-17
dc.identifier.issn1748-6963
dc.identifier.other24364871
dc.identifier.urihttps://doi.org/10.2217/nnm.13.167
dc.identifier.urihttp://dspace.nm-aist.ac.tz/handle/123456789/491
dc.descriptionResearch Article published by NANOMEDICINEVOL. 9, NO. 12en_US
dc.description.abstractAim: To encapsulate efavirenz (EFV) within poly(epsilon-caprolactone) (PCL) nanoparticles (NPs) and compare the oral pharmacokinetics with that of EFV-loaded micelles and pure EFV NPs. Materials & methods: EFV-loaded PCL NPs were produced by a double-emulsion/spray-drying method. Results: NPs displayed a hydrodynamic diameter of 200–250 nm. The encapsulation efficiency was 86–93% and the mass recovery was above 60%. X-ray diffraction indicated that drug and PCL underwent amorphization during the spray-drying process. Encapsulation within NPs significantly increased the maximum concentration in plasma and the bioavailability. Conclusion: EFV-loaded PCL NPs represent a promising platform to develop scalable pharmaceuticals with improved (bio)pharmaceutic performance.en_US
dc.language.isoenen_US
dc.publisherNANOMEDICINEen_US
dc.subjectHIVen_US
dc.subjectEfavirenzen_US
dc.subjectIn vitro drug releaseen_US
dc.subjectOral bioavailability enhancementen_US
dc.subjectPoly(epsilon-caprolactone) nanoparticleen_US
dc.subjectSpray dryingen_US
dc.titleEnhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method.en_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record